Barclays
ARTV icon

Barclays’s Artiva Biotherapeutics ARTV Stock Holding History

Barclays’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$54K Buy
7,588
+4,252
+127% +$42.9K ﹤0.01% 4549
2026
Q2 		$32.4K Buy
+3,336
New +$30.4K ﹤0.01% 4465
2025
Q4 		– Sell
-12,696
Closed -$36.4K – 5789
2025
Q3 		$36.4K Buy
12,696
+10,790
+566% +$28.9K ﹤0.01% 4845
2025
Q2 		$2.88K Sell
1,906
-20,847
-92% -$43.8K ﹤0.01% 5013
2025
Q1 		$68.3K Sell
22,753
-1,408
-6% -$7.6K ﹤0.01% 4526
2024
Q4 		$244K Buy
24,161
+4,545
+23% +$54.6K ﹤0.01% 4216
2024
Q3 		$303K Buy
+19,616
New +$227K ﹤0.01% 4084

Other funds holding ARTV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's ARTV Position: Q3 2026 in Review

Barclays increased its Artiva Biotherapeutics (ARTV) stake by 127% in Q3 2026, buying an estimated $42.9K and bringing the position to 7,588 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #4549.

Barclays first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $303K in Q3 2024. 27 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Barclays held 7,588 shares of Artiva Biotherapeutics worth $54K as of Q3 2026.
  • Barclays bought 4,252 Artiva Biotherapeutics shares in Q3 2026, an estimated $42.9K.
  • Artiva Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4549 holding.
  • Barclays first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Barclays's Artiva Biotherapeutics position peaked at $303K in Q3 2024.
  • 27 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.